Simulations Plus (SLP) Peer Comparison
$18.42
$0.01
(0.05%)
As on 27-Aug-2026 16:00EDT
Market cap
$372 Mln
Revenue (TTM)
$82 Mln
P/E Ratio
46
P/B Ratio
2.7
Div. Yield
0 %
Edit
| Simulations Plus (SLP) | Neogen (NEOG) | AngioDynamics (ANGO) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
372 | 2,606 | 651 | 34 | 32,953 |
Revenue ($ Mln) |
82 | 870 | 320 | 402 | 5,653 |
Net Profit ($ Mln) |
8.11 | -7.90 | -36.74 | -49.19 | 1,523.29 |
Net Margin (%) |
9.88 | -0.91 | -11.48 | -12.24 | 26.94 |
RoE (%) |
6.09 | -0.38 | -20.77 | -80.08 | 24.27 |
Price to Earnings |
46.00 | -- | -- | -- | 22.11 |
Price-To-Book |
2.68 | 1.23 | 3.81 | 0.84 | 5.05 |
Income Statement ($ Mln)
| Simulations Plus (SLP) | Neogen (NEOG) | AngioDynamics (ANGO) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
79.18 | 894.66 | 292.50 | 401.95 | 5,653.44 |
|
Cost of Revenue
|
32.96 | 473.29 | 134.79 | 290.49 | 2,195.77 |
|
Gross Profit
|
46.22 | 421.38 | 157.71 | 146.97 | 3,054.97 |
|
Operating Expenses
|
116.95 | 411.96 | 197.66 | 137.90 | 1,565.03 |
|
Operating Profit (EBIT)
|
-70.73 | 9.42 | -39.95 | -26.44 | 1,892.65 |
|
Other Income
|
-- | -- | -- | 0.00 | 0.00 |
|
Profit before Tax
|
-69.38 | -1,133.11 | -34.03 | -47.25 | 1,919.42 |
|
Provision for Tax
|
-4.66 | -41.07 | -0.04 | 1.95 | 396.12 |
|
Profit after Tax (Net Income)
|
-64.72 | -1,092.04 | -33.99 | -49.19 | 1,523.29 |
|
Minority Interest
|
-- | -- | -- | 0.00 | 0.00 |
|
Consolidated Profit
|
-- | -- | -- | 0.00 | 741.13 |
Liabilities ($ Mln)
| Simulations Plus (SLP) | Neogen (NEOG) | AngioDynamics (ANGO) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
124.80 | 2,071.25 | 182.97 | 41.70 | 6,585.39 |
|
Minority Interest
|
-- | -- | -- | 0.00 | 0.00 |
|
Non-Current Liabilities
|
0.41 | 1,198.57 | 20.98 | 210.57 | 985.45 |
|
Current Liabilities
|
6.73 | 174.01 | 76.20 | 191.41 | 1,395.11 |
|
Total Liabilities
|
131.94 | 3,443.84 | 280.14 | 470.24 | 8,174.39 |
Assets ($ Mln)
| Simulations Plus (SLP) | Neogen (NEOG) | AngioDynamics (ANGO) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
80.39 | 2,866.90 | 111.82 | 155.90 | 4,641.21 |
|
Current Assets
|
51.55 | 576.94 | 168.32 | 287.78 | 4,324.74 |
|
Total Assets
|
131.94 | 3,443.84 | 280.14 | 470.24 | 8,174.39 |
|
Total Debt*
|
0.62 | 912.61 | 10.15 | 183.87 | 825.92 |
|
Net Current Assets
|
44.82 | 402.93 | 92.13 | 0.00 | 0.00 |
Cashflow ($ Mln)
| Simulations Plus (SLP) | Neogen (NEOG) | AngioDynamics (ANGO) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
18.13 | 58.24 | -10.13 | 2.86 | 1,751.59 |
|
Cash Flow from Investing Activities
|
3.56 | -99.20 | -10.18 | -8.52 | -200.05 |
|
Cash from Financing Activities
|
-1.15 | -1.60 | -0.26 | -4.25 | -606.25 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Simulations Plus (SLP) | Neogen (NEOG) | AngioDynamics (ANGO) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-41.91 | -31.05 | -16.85 | -0.62 | 22.31 |
|
ROE (%)
|
-42.13 | -41.88 | -17.50 | -103.44 | 23.61 |
|
ROA (%)
|
-38.12 | -27.33 | -11.37 | -7.06 | 13.55 |
|
EBIT Margin (%)
|
-- | -- | -- | -3.57 | 34.46 |
|
Net Margin (%)
|
-81.74 | -122.06 | -11.62 | -12.24 | 26.94 |
|
Cash Profit Margin (%)
|
-- | -- | -- | 0.00 | 0.00 |
Growth Ratios
| Simulations Plus (SLP) | Neogen (NEOG) | AngioDynamics (ANGO) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.13 | -0.03 | -0.04 | -12.34 | 9.85 |
|
EBIT Growth (%)
|
-- | -- | -- | -201.81 | 15.44 |
|
Net Profit Growth (%)
|
-750.17 | -11,491.59 | 81.56 | -2,992.02 | 8.75 |
|
EPS Growth (%)
|
-- | -- | -- | -2,257.66 | 9.37 |
|
Book Value Growth (%)
|
-- | -- | -- | -54.38 | 11.92 |
Valuation Ratios
| Simulations Plus (SLP) | Neogen (NEOG) | AngioDynamics (ANGO) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -- | -- | -93.77 | 27.08 |
|
Price / Book Value
|
-- | -- | -- | 1.84 | 6.36 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-2.16 | -0.84 | -26.32 | 13.25 | 19.63 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Simulations Plus (SLP) | Neogen (NEOG) | AngioDynamics (ANGO) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.44 | 0.06 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
0.00 | 0.01 | 0.01 | 0.23 | 0.04 |
|
Current Ratio
|
7.67 | 3.32 | 2.21 | 1.50 | 3.10 |
|
Quick Ratio
|
2.77 | 2.22 | 1.40 | 0.74 | 2.42 |
|
Interest Coverage
|
-- | -14.85 | -20.97 | -0.34 | 39.45 |
Operating Efficiency Ratios
| Simulations Plus (SLP) | Neogen (NEOG) | AngioDynamics (ANGO) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
18.46 | 17.14 | 14.75 | 16.77 | 18.33 |
|
Asset Turnover
|
0.47 | 0.22 | 0.98 | 0.58 | 0.50 |
|
Receivable days
|
54.79 | 66.63 | 58.16 | 78.36 | 64.87 |
|
Inventory Days
|
65.39 | 146.68 | 166.14 | 163.75 | 152.81 |
|
Payable days
|
5.94 | 62.77 | 96.25 | 49.27 | 45.05 |
|
Cash Conversion Cycle
|
114.23 | 150.54 | 128.04 | 192.84 | 172.63 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
